John S Thurlow1,2, Megha Joshi1,2, Guofen Yan3, Keith C Norris4, Lawrence Y Agodoa5, Christina M Yuan1,2, Robert Nee6,7. 1. Nephrology Service, Walter Reed National Military Medical Center, Bethesda, Maryland, USA. 2. Department of Medicine, Uniformed Services University, Bethesda, Maryland, USA. 3. Department of Public Health Sciences, University of Virginia School of Medicine, Charlottesville, Virginia, USA. 4. Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA. 5. Office of the Director, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA. 6. Nephrology Service, Walter Reed National Military Medical Center, Bethesda, Maryland, USA, robert.nee.civ@mail.mil. 7. Department of Medicine, Uniformed Services University, Bethesda, Maryland, USA, robert.nee.civ@mail.mil.
Abstract
BACKGROUND: The global epidemiology of end-stage kidney disease (ESKD) reflects each nation's unique genetic, environmental, lifestyle, and sociodemographic characteristics. The response to ESKD, particularly regarding kidney replacement therapy (KRT), depends on local disease burden, culture, and socioeconomics. Here, we explore geographic variation and global trends in ESKD incidence and prevalence and examine variations in KRT modality, practice patterns, and mortality. We conclude with a discussion on disparities in access to KRT and strategies to reduce ESKD global burden and to improve access to treatment in low- and middle-income countries (LMICs). SUMMARY: From 2003 to 2016, incidence rates of treated ESKD were relatively stable in many higher income countries but rose substantially predominantly in East and Southeast Asia. The prevalence of treated ESKD has increased worldwide, likely due to improving ESKD survival, population demographic shifts, higher prevalence of ESKD risk factors, and increasing KRT access in countries with growing economies. Unadjusted 5-year survival of ESKD patients on KRT was 41% in the USA, 48% in Europe, and 60% in Japan. Dialysis is the predominant KRT in most countries, with hemodialysis being the most common modality. Variations in dialysis practice patterns account for some of the differences in survival outcomes globally. Worldwide, there is a greater prevalence of KRT at higher income levels, and the number of people who die prematurely because of lack of KRT access is estimated at up to 3 times higher than the number who receive treatment. Key Messages: Many people worldwide in need of KRT as a life-sustaining treatment do not receive it, mostly in LMICs where health care resources are severely limited. This large treatment gap demands a focus on population-based prevention strategies and development of affordable and cost-effective KRT. Achieving global equity in KRT access will require concerted efforts in advocating effective public policy, health care delivery, workforce capacity, education, research, and support from the government, private sector, nongovernmental, and professional organizations.
BACKGROUND: The global epidemiology of end-stage kidney disease (ESKD) reflects each nation's unique genetic, environmental, lifestyle, and sociodemographic characteristics. The response to ESKD, particularly regarding kidney replacement therapy (KRT), depends on local disease burden, culture, and socioeconomics. Here, we explore geographic variation and global trends in ESKD incidence and prevalence and examine variations in KRT modality, practice patterns, and mortality. We conclude with a discussion on disparities in access to KRT and strategies to reduce ESKD global burden and to improve access to treatment in low- and middle-income countries (LMICs). SUMMARY: From 2003 to 2016, incidence rates of treated ESKD were relatively stable in many higher income countries but rose substantially predominantly in East and Southeast Asia. The prevalence of treated ESKD has increased worldwide, likely due to improving ESKD survival, population demographic shifts, higher prevalence of ESKD risk factors, and increasing KRT access in countries with growing economies. Unadjusted 5-year survival of ESKD patients on KRT was 41% in the USA, 48% in Europe, and 60% in Japan. Dialysis is the predominant KRT in most countries, with hemodialysis being the most common modality. Variations in dialysis practice patterns account for some of the differences in survival outcomes globally. Worldwide, there is a greater prevalence of KRT at higher income levels, and the number of people who die prematurely because of lack of KRT access is estimated at up to 3 times higher than the number who receive treatment. Key Messages: Many people worldwide in need of KRT as a life-sustaining treatment do not receive it, mostly in LMICs where health care resources are severely limited. This large treatment gap demands a focus on population-based prevention strategies and development of affordable and cost-effective KRT. Achieving global equity in KRT access will require concerted efforts in advocating effective public policy, health care delivery, workforce capacity, education, research, and support from the government, private sector, nongovernmental, and professional organizations.
Authors: Thaminda Liyanage; Toshiharu Ninomiya; Vivekanand Jha; Bruce Neal; Halle Marie Patrice; Ikechi Okpechi; Ming-hui Zhao; Jicheng Lv; Amit X Garg; John Knight; Anthony Rodgers; Martin Gallagher; Sradha Kotwal; Alan Cass; Vlado Perkovic Journal: Lancet Date: 2015-03-13 Impact factor: 79.321
Authors: Steven M Brunelli; Glenn M Chertow; Elizabeth D Ankers; Edmund G Lowrie; Ravi Thadhani Journal: Kidney Int Date: 2010-01-20 Impact factor: 10.612
Authors: Charles R Swanepoel; Mignon I McCulloch; Georgi Abraham; Jo-Ann Donner; Mona N Alrukhaimi; Peter G Blake; Sakarn Bunnag; Stefaan Claus; Gavin Dreyer; Mohammad A Ghnaimat; Fuad M Ibhais; Adrian Liew; Marla McKnight; Yewondwossen Tadesse Mengistu; Saraladevi Naicker; Abdou Niang; Gregorio T Obrador; Jeffrey Perl; Harun Ur Rashid; Marcello Tonelli; Kriang Tungsanga; Tushar Vachharajani; Elena Zakharova; Carlos Zuniga; Fredric O Finkelstein Journal: Kidney Int Suppl (2011) Date: 2020-02-19
Authors: M Razeen Davids; John B Eastwood; Neville H Selwood; Fatiu A Arogundade; Gloria Ashuntantang; Mohammed Benghanem Gharbi; Faiçal Jarraya; Iain A M MacPhee; Mignon McCulloch; Jacob Plange-Rhule; Charles R Swanepoel; Dwomoa Adu Journal: Clin Kidney J Date: 2015-11-25
Authors: Alberto Ortiz; Juan F Navarro-González; Julio Núñez; Rafael de la Espriella; Marta Cobo; Rafael Santamaría; Patricia de Sequera; Javier Díez Journal: Clin Kidney J Date: 2021-12-23
Authors: Debasish Banerjee; Peter Winocour; Tahseen A Chowdhury; Parijat De; Mona Wahba; Rosa Montero; Damian Fogarty; Andrew Frankel; Gabrielle Goldet; Janaka Karalliedde; Patrick B Mark; Dipesh Patel; Ana Pokrajac; Adnan Sharif; Sagen Zac-Varghese; Stephen Bain; Indranil Dasgupta Journal: Kidney Int Rep Date: 2022-01-13